期刊
MOLECULAR THERAPY
卷 29, 期 9, 页码 2640-2659出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2021.08.003
关键词
-
资金
- Tehran University of Medical Sciences [50756, 50760]
- National Institute for Medical Research Development (NIMAD) of Iran [996475]
- St. Baldrick's Foundation Scholar Award
- National Blood Foundation Scientific Research Grant Award
- Office of the Assistant Secretary of Defense for Health Affairs through the Peer-Reviewed Cancer Research Program [W81XWH-20-1-0417]
This article discusses the role of epigenetics in CAR T cell therapy, highlighting the crucial role of epigenetic remodeling in T cell differentiation and how modifications can alter immune responses. Selective epigenetic modifications can overcome limitations of CAR T cells in immunosuppressive tumor microenvironments, ultimately enhancing the efficacy of CAR T cell therapy.
Chimeric antigen receptor (CAR) T cell therapy has led to a paradigm shift in cancer immunotherapy, but still several obstacles limit CAR T cell efficacy in cancers. Advances in high throughput technologies revealed new insights into the role that epigenetic reprogramming plays in T cells. Mechanistic studies as well as comprehensive epigenome maps revealed an important role for epigenetic remodeling in T cell differentiation. These modifications shape the overall immune response through alterations in T cell phenotype and function. Here, we outline how epigenetic modifications in CAR T cells can overcome barriers limiting CAR T cell effectiveness, particularly in immunosuppressive tumor microenvironments. We also offer our perspective on how selected epigenetic modifications can boost CAR T cells to ultimately improve the efficacy of CAR T cell therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据